Vivek R. Sharma

1.2k total citations
52 papers, 777 citations indexed

About

Vivek R. Sharma is a scholar working on Hematology, Surgery and Oncology. According to data from OpenAlex, Vivek R. Sharma has authored 52 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 13 papers in Surgery and 10 papers in Oncology. Recurrent topics in Vivek R. Sharma's work include Complement system in diseases (8 papers), Cancer Genomics and Diagnostics (7 papers) and Platelet Disorders and Treatments (7 papers). Vivek R. Sharma is often cited by papers focused on Complement system in diseases (8 papers), Cancer Genomics and Diagnostics (7 papers) and Platelet Disorders and Treatments (7 papers). Vivek R. Sharma collaborates with scholars based in United States, India and France. Vivek R. Sharma's co-authors include Donald R. Fleming, Stephen P. Slone, Charles R. Scoggins, Robert C.G. Martin, Clifton M. Tatum, Marshall T. Schreeder, Nishant Tiwari, Sanjay Kumar Agarwal, Sanat Phatak and Todd S. Crocenzi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Vivek R. Sharma

49 papers receiving 749 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vivek R. Sharma United States 14 193 179 176 163 152 52 777
Attaphol Pawarode United States 17 244 1.3× 342 1.9× 297 1.7× 459 2.8× 229 1.5× 64 1.1k
CK Lee South Korea 16 160 0.8× 63 0.4× 238 1.4× 99 0.6× 186 1.2× 40 939
Jurjen Versluis Netherlands 13 305 1.6× 91 0.5× 48 0.3× 240 1.5× 249 1.6× 43 747
Toshiki Yamada Japan 18 336 1.7× 105 0.6× 100 0.6× 441 2.7× 274 1.8× 61 1.1k
Önder Arslan Türkiye 16 159 0.8× 132 0.7× 76 0.4× 354 2.2× 124 0.8× 81 779
Kimikazu Matsumoto Japan 20 237 1.2× 58 0.3× 122 0.7× 567 3.5× 117 0.8× 122 1.3k
Verena Bröcker Germany 18 256 1.3× 45 0.3× 371 2.1× 57 0.3× 228 1.5× 38 1.1k
Giuseppe Monti Italy 19 123 0.6× 594 3.3× 224 1.3× 140 0.9× 128 0.8× 56 1.2k
Themistoklis Spyridopoulos Greece 14 153 0.8× 206 1.2× 202 1.1× 48 0.3× 93 0.6× 20 826
Masanobu Tsuda Japan 21 125 0.6× 427 2.4× 229 1.3× 73 0.4× 402 2.6× 33 1.1k

Countries citing papers authored by Vivek R. Sharma

Since Specialization
Citations

This map shows the geographic impact of Vivek R. Sharma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek R. Sharma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek R. Sharma more than expected).

Fields of papers citing papers by Vivek R. Sharma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivek R. Sharma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek R. Sharma. The network helps show where Vivek R. Sharma may publish in the future.

Co-authorship network of co-authors of Vivek R. Sharma

This figure shows the co-authorship network connecting the top 25 collaborators of Vivek R. Sharma. A scholar is included among the top collaborators of Vivek R. Sharma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek R. Sharma. Vivek R. Sharma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chakrabarti, Sakti, Stacey A. Cohen, Antony Tin, et al.. (2024). Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery.. Journal of Clinical Oncology. 42(3_suppl). 212–212. 1 indexed citations
3.
Vohra, Ishaan, et al.. (2023). Impact of malnutrition on postoperative outcomes of patients undergoing gastrectomy for gastric cancer: A nationwide analysis between 2012 and 2017.. Journal of Clinical Oncology. 41(4_suppl). 315–315. 1 indexed citations
4.
Sharma, Vivek R., et al.. (2023). Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report. Advances in Therapy. 40(11). 5115–5129. 1 indexed citations
5.
Cohen, Stacey A., Pashtoon Murtaza Kasi, Vasily N. Aushev, et al.. (2023). Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer.. Journal of Clinical Oncology. 41(4_suppl). 5–5. 11 indexed citations
6.
Martin, Robert C.G., Kerri A. Simo, Paul Hansen, et al.. (2022). Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin. Annals of Surgical Oncology. 29(9). 5462–5473. 24 indexed citations
7.
Shesh, N., et al.. (2021). Predictors of thrombosis in patients treated with bevacizumab. SHILAP Revista de lepidopterología. 6. 100095–100095. 2 indexed citations
8.
Asamoah, Alexander, et al.. (2020). Emicizumab Associated Rhabdomyolysis in Hemophilia A. SHILAP Revista de lepidopterología. 2(4). 165–165. 1 indexed citations
9.
Tiwari, Nishant, et al.. (2020). Antiplatelet Agents in Sepsis—Putting it all together: A Call to Action. Indian Journal of Critical Care Medicine. 24(6). 483–484. 4 indexed citations
10.
Singh, Vikas & Vivek R. Sharma. (2019). Gemcitabine, docetaxel, and capecitabine (GTX) as a first-line regimen in metastatic pancreatic adenocarcinomas (mPAC): A single institution experience.. Journal of Clinical Oncology. 37(4_suppl). 385–385. 1 indexed citations
11.
Sharma, Vivek R., et al.. (2017). Cardiomyopathy and anaesthesia. BJA Education. 17(11). 363–369. 5 indexed citations
12.
Redman, Rebecca, et al.. (2015). Preemptive therapy of cetuximab-induced skin rash using doxycycline, sunscreen, hydrocortisone, and moisturizer in colorectal and head and neck cancer patients.. Journal of Clinical Oncology. 33(3_suppl). TPS796–TPS796. 1 indexed citations
13.
Claudino, Wederson M., Ajoy Dias, William Tse, & Vivek R. Sharma. (2015). Type B lactic acidosis: a rare but life threatening hematologic emergency. A case illustration and brief review.. PubMed. 5(1). 25–9. 29 indexed citations
14.
Sharma, Vivek R., et al.. (2014). A combination of bortezomib and rituximab yields a dramatic response in a woman with highly refractory immune thrombocytopenic purpura: a case report. Journal of Medical Case Reports. 8(1). 19–19. 5 indexed citations
15.
Sharma, Vivek R., et al.. (2012). Cobalamin deficiency presenting as obsessive compulsive disorder: case report. General Hospital Psychiatry. 34(5). 578.e7–578.e8. 10 indexed citations
16.
Martin, Robert C.G., Charles R. Scoggins, Dana Tomalty, et al.. (2012). Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial. Journal of Gastrointestinal Surgery. 16(8). 1531–1538. 58 indexed citations
17.
18.
Civelek, A. Cahid, et al.. (2011). A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent Advanced Squamous Cell Cancer of the Anal Canal. PubMed. 2011. 1–6. 13 indexed citations
19.
Laber, Damian A., et al.. (2004). A phase I study of AGRO100 in advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 3112–3112. 15 indexed citations
20.
Sharma, Vivek R., Donald R. Fleming, & Stephen P. Slone. (2000). Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood. 96(3). 1184–1186. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Attaphol Pawarode Breakdown of academic impact, for papers by CK Lee Breakdown of academic impact, for papers by Jurjen Versluis Breakdown of academic impact, for papers by Toshiki Yamada Breakdown of academic impact, for papers by Önder Arslan Breakdown of academic impact, for papers by Kimikazu Matsumoto Breakdown of academic impact, for papers by Verena Bröcker Breakdown of academic impact, for papers by Giuseppe Monti Breakdown of academic impact, for papers by Themistoklis Spyridopoulos Breakdown of academic impact, for papers by Masanobu Tsuda
Rankless by CCL
2026